In the Suboxone case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a class of direct purchasers of Reckitt Benckiser’s opioid addiction drug, Suboxone. The class alleges that Reckitt took several actions to suppress competition from generic versions of Suboxone, including reformulating Suboxone into a film (for which generic versions of Suboxone tablets could not be substituted by pharmacists), sabotaging efforts to create a joint REMS program, and filing a baseless citizens petition. Faruqi & Faruqi was appointed co-lead counsel by the Court.
Suboxone EDPa Class Certification Opinion
Suboxone Third Circuit Class Certification Order
Suboxone Third Circuit Class Certification Opinion
Suboxone Motion for Preliminary Approval of Settlement
Suboxone Order Granting Preliminary Approval of Settlement
Class Counsel Motion for Attorneys' Fees
Opinion and Order of Final Approval of Settlement, Attorney Fees and Incentive Awards
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 03/05/2013
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771